Casgevy, Red blood cell and NHS England

Sickle cell gene therapy Casgevy finally cleared for NHS use
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme and with a confidential discount.
NHS England to offer Casgevy for sickle cell disease patients
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy,
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
'Groundbreaking' sickle cell treatment to be offered on NHS
A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England
Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
A £1.65m hope for blood disorder patients is now on offer in Manchester
A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...